Pharsight

Drugs that contain Palonosetron Hydrochloride

1. Aloxi patents expiration

ALOXI's oppositions filed in EPO
ALOXI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5202333 HELSINN HLTHCARE Tricyclic 5-HT3 receptor antagonists
Apr, 2015

(9 years ago)

US5202333

(Pediatric)

HELSINN HLTHCARE Tricyclic 5-HT3 receptor antagonists
Oct, 2015

(8 years ago)

US7960424 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US8598219 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9066980 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US8729094 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9457021 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US7947725 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9125905 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US8518981 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9439854 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US8598218 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9173942 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9457020 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US7947724 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(3 months ago)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-684) May 27, 2017
M(M-136) May 27, 2017
Pediatric Exclusivity(PED) Nov 27, 2017

Market Authorisation Date: 29 February, 2008

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS; CAPSULE;ORAL

How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage

ALOXI family patents

Family Patents